| Market Cap | 14.98M | P/E | - | EPS this Y | -44.30% | Ern Qtrly Grth | - |
| Income | -16.58M | Forward P/E | -0.96 | EPS next Y | 42.50% | 50D Avg Chg | 12.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -62.00% |
| Dividend | N/A | Price/Book | 0.73 | EPS next 5Y | - | 52W High Chg | -99.00% |
| Recommedations | 1.50 | Quick Ratio | 2.35 | Shares Outstanding | 8.22M | 52W Low Chg | 52.00% |
| Insider Own | 67.86% | ROA | -52.18% | Shares Float | 1.19M | Beta | -0.29 |
| Inst Own | 9.60% | ROE | -108.42% | Shares Shorted/Prior | 52.67K/58.54K | Price | 0.55 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 380,464 | Target Price | 27.67 |
| Oper. Margin | - | Earnings Date | Aug 7 | Volume | 1,373,472 | Change | 9.69% |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
| Maxim Group | Buy | May 8, 24 |